UBS Group
CLDI icon

UBS Group’s Calidi Biotherapeutics CLDI Stock Holding History

UBS Group’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,514
Closed -$8.79K – 10570
2025
Q4 		$8.79K Buy
7,514
+4,950
+193% +$7.28K ﹤0.01% 8334
2025
Q3 		$3.9K Sell
2,564
-1,178
-31% -$5K ﹤0.01% 8996
2025
Q2 		$10.3K Buy
+3,742
New +$18.2K ﹤0.01% 8845
2025
Q1 		– Sell
-733
Closed -$8.36K – 10161
2024
Q4 		$10.1K Buy
733
+656
+852% +$12.3K ﹤0.01% 8318
2024
Q3 		$1.05K Buy
+77
New +$1.34K ﹤0.01% 8733
2024
Q2 		– Hold
0
– – – 9418
2024
Q1 		– Hold
0
– – – 9132
2023
Q4 		– Hold
0
– – – 9090
2023
Q3 		– Hold
0
– – – 9064
2023
Q2 		– Hold
0
– – – 8497
2023
Q1 		– Hold
0
– – – 9220
2022
Q4 		– Hold
0
– – – 10284
2022
Q3 		– Sell
-13
Closed -$16K – 10396
2022
Q2 		$16K Hold
13
– – ﹤0.01% 7181
2022
Q1 		$15K Sell
13
-49
-79% -$57.9K ﹤0.01% 7819
2021
Q4 		$73K Buy
+62
New +$73.1K ﹤0.01% 6570

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's CLDI Position: Q1 2026 in Review

UBS Group sold out of Calidi Biotherapeutics (CLDI) in Q1 2026, closing a stake of 7,514 shares — an estimated $8.79K sold.

UBS Group first reported a position in CLDI in Q4 2021 and held it in 8 quarters. The position peaked at $73K in Q4 2021. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • UBS Group reported no remaining Calidi Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 7,514 Calidi Biotherapeutics shares in Q1 2026, an estimated $8.79K.
  • UBS Group first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 8 quarters.
  • UBS Group's Calidi Biotherapeutics position peaked at $73K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.